Labcorp, Pillar Biosciences team up for genomic testing
October 19, 2021 -- Labcorp and Pillar Biosciences have signed an agreement to offer genomic cancer testing based on Pillar's next-generation sequencing technology. Read More
Caris, Essa introduce program for prostate cancer inhibitor
October 8, 2021 -- Caris Life Sciences and Essa Pharma are introducing a precision development program to support the latter's ongoing clinical development of EPI-7386. Read More
Illumina, Merck partner on HRD test
September 8, 2021 -- Illumina and Merck have agreed to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Read More
NGS is transforming diagnostics, but is it right for everyone?
September 1, 2021 -- As clinical laboratories embrace genetic testing to improve their diagnosis of disease, many are turning to next-generation sequencing (NGS) to speed diagnosis. But does every diagnostic laboratory have the volume to justify investing in NGS technology, where hardware and software costs can run several hundred thousands of dollars at a minimum? Read More
Thermo Fisher, AstraZeneca to develop NGS companion diagnostics
September 1, 2021 -- Thermo Fisher Scientific and AstraZeneca plan to co-develop companion diagnostics based on next-generation sequencing (NGS) to support targeted therapies. Read More
COVIDome Explorer lets public decipher COVID pathology
August 23, 2021 -- A new multidimensional dataset for COVID-19 multiomics research has been released to the public, along with a free online research portal for analyzing the data. The COVIDome Explorer and dataset give researchers a way to share data and collaborate in real-time for the clinical management of COVID-19. Read More
Illumina completes Grail deal, despite lack of European approval
August 18, 2021 -- Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail as a separate company as the European Commission continues to review the deal. Read More
NYU Langone genetic cancer test gets FDA 510(k) clearance
July 29, 2021 -- An NYU Langone Health genetic test for all solid cancers has received U.S. Food and Drug Administration (FDA) 510(k) clearance. The gene sequencing test is designed to guide treatment decisions for patients who have received a cancer diagnosis. Read More
Liquid biopsy may detect ALK fusions in lung cancer patients
July 28, 2021 -- The use of next-generation sequencing-based circulating-tumor DNA in liquid biopsies may detect novel anaplastic lymphoma kinase (ALK) fusions in lung cancer patients, according to a study published in Lung Cancer on July 27. Read More
Premier Medical names new chief scientific officer
July 28, 2021 -- Premier Medical Laboratory Services has named Brian Krueger as its new chief scientific officer. Read More